Key Developments: IsoRay Inc (ISR)
0.48USD
24 May 2013
$-0.02 (-3.58%)
$0.50
$0.48
$0.50
$0.48
33,500
129,985
$1.60
$0.35
Latest Key Developments (Source: Significant Developments)
IsoRay Inc Announces New International Distributor For Greece
IsoRay Inc announced that it has entered into an exclusive international distribution agreement with IASIS Medical for the sale of IsoRay's complete product line in Greece. IsoRay is a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for brain cancer, lung cancer, head and neck cancer, prostate cancer and gynecologic (gyn) cancer. Full Article
IsoRay, Inc. Announces Financing Of $3.5 Million To Advance Its GliaSite and New Emerging Cancer Solutions For Internal Radiation Therapy
IsoRay, Inc. announced that it has entered into agreements with certain institutional investors for a registered direct placement of approximately $3.5 million of common stock at a price of $0.965 per share. Gross proceeds will be approximately $3.5 million, before deducting placement agent's fees and estimated offering expenses. A more complete description of the terms and conditions for the financing are available in the Form 8-K filed by the Company. The offering is expected to close on or about July 19, 2012, subject to satisfaction of customary closing conditions. Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc., acted as the exclusive placement agent for the transaction. Full Article
IsoRay, Inc. Receives Final Regulatory Approval for GliaSite Brain Cancer Treatment
IsoRay, Inc. announced that it has received final approval from the State of Washington Department of Health to manufacture its GliaSite radiation therapy system, a balloon catheter device used in the treatment of brain cancer. In conjunction with the previously announced FDA clearance, the Washington State approval represents IsoRay`s final regulatory hurdle to commence the sale of its GliaSite brain cancer treatment in the United States. GliaSite is a landmark technology that allows physicians to treat more brain cancer patients than ever before with internal radiation or brachytherapy. Full Article
IsoRay, Inc. Announces International Distribution Agreement For GliaSite
IsoRay, Inc. announced that it has entered into an international distribution agreement with Karlheinz Goehl-Medizintechnik Goehl for distribution in certain European markets of the GliaSite radiation therapy system, the balloon catheter device used in the treatment of various brain cancers. The system’s balloon catheter is an technology that allows physicians to treat more patients than ever before with brachytherapy or internal radiation therapy. Full Article
IsoRay, Inc. Announces Financing For $2.3 Million
IsoRay, Inc. announced the execution of an underwriting agreement with WestPark Capital, Inc., as managing underwriter, to sell approximately $2.3 million in common stock and warrants to purchase shares of common stock which, if fully exercised, will raise an additional approximate $460,000. IsoRay has also granted the underwriters a 45-day option to purchase up to an additional 1,027,173 shares of common stock and warrants to purchase up to an additional 205,435 shares of common stock to cover over-allotments, if any. Under the terms of the agreement, the Company will immediately sell 2.5 million shares of its common stock at $0.92 per share in a financing with gross proceeds of $2.3 million, which represents a 4% discount to the closing price on October 11, 2011. Additionally, as part of the transaction, the investors also will receive one warrant for each five shares purchased, exercisable up to five years following the closing at approximately $1.06 per share. A more complete description of the terms and conditions for this financing are available in the Form 8-K filed by the Company. The Company will receive additional net proceeds of approximately $400,000 assuming all warrants are exercised and the over-allotment is not sold. The offering is expected to close on or about October 14, 2011 subject to customary closing conditions. Full Article
IsoRay, Inc. Completes License Agreement With Dr. Reddy’s Laboratories For Exclusive Worldwide Licensing Rights To Iotrex
IsoRay, Inc. announced that it has completed a license agreement with Dr. Reddy’s Laboratories, for exclusive worldwide licensing rights to Iotrex, a liquid iodine radiation, for use in brain cancer treatment. Iotrex is a critical component in the GliaSite radiation therapy system, the world's only FDA-cleared balloon catheter device used in the treatment of many forms of brain cancer. IsoRay has exclusive worldwide distribution rights to the GliaSite therapy system. The Iotrex licensing agreement is a major step in the process needed to allow IsoRay to make its submission to the FDA for final approval as it moves toward the anticipated launch of its GliaSite sales initiative in August. Full Article
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
